HC Wainwright & Co. Reiterates Buy on Sensei Biotherapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Sensei Biotherapeutics (NASDAQ:SNSE) and maintained a $4 price target.
August 07, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Sensei Biotherapeutics and maintained a $4 price target.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100